Aurinia Pharmaceuticals (AUPH) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 116.5% versus a gain of 40.7%. Over five years, AUPH leads with a -21.1% price change compared with -80.6% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.67 billion vs $2.16 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | MRVI |
|---|---|---|
| Share price | $16.22 | $7.21 |
| Market cap | $2.16B | $2.67B |
| 1-day change | +1.31% | -2.96% |
| YTD return | +1.69% | +121.85% |
| 1-year return | +40.68% | +116.52% |
| 5-year return | -21.15% | -80.56% |
| P/E ratio (TTM) | 7.11 | — |
| Forward P/E | 15.21 | — |
| EPS (TTM) | $2.28 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | — | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $19.25 | $9.42 |
| 52-week low | $10.90 | $2.55 |
| Distance from 52-week high | -15.74% | -23.46% |
| Analyst consensus | none | buy |
| Avg. price target upside | +10.11% | +8.60% |
| Average volume | 988.90K | 3.36M |
| Shares outstanding | 133.05M | 148.99M |
| Employees | 128 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed AUPH by 75.8 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
AUPH vs MRVI FAQ
Which is bigger, Aurinia Pharmaceuticals or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.67B compared with $2.16B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or MRVI?
MRVI returned +116.52% over the past 12 months, compared with +40.68% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.